{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-089218","form_type":"8-K","ticker":"AMRN","cik":"0000897448","company_name":"AMARIN CORP PLCUK","filed_at":"2025-06-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.724971+00:00","generated_at":"2026-05-18T23:10:55.431082+00:00","sec_items":["1.01","2.05","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Amarin licenses VAZKEPA to Recordati in Europe; launches restructuring targeting $70M annual savings","bullets":["Upfront $25M and up to $150M in milestone payments; Recordati to commercialize VAZKEPA in 59 European countries.","Global restructuring to cut operating costs by ~$70M annually; expects $30-37M in restructuring charges in Q2 2025.","Company retains U.S. rights; nearly $300M cash on hand, no debt; accelerated path to positive cash flow.","Agreement term 15 years, auto-renewal subject to commercialization in at least one country."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-089218","json":"https://secwatch.observer/filing/0000950170-25-089218.json","markdown":"https://secwatch.observer/filing/0000950170-25-089218.md","text":"https://secwatch.observer/filing/0000950170-25-089218.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/897448/000095017025089218/0000950170-25-089218-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/897448/000095017025089218/amrn-20250620.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T23:10:55.431082+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4f3fc8a92edbc3d49f4a58048a5b1e3bde4317c2","claim":"AMARIN CORP PLCUK announced a restructuring with charges of between approximately $30 million and $37 million affecting Europe operations.","evidence_excerpt":"On June 24, 2025, as described in the Press Release, the Company announced a global restructuring, with the vast majority of estimated cost savings from reduced commercialization expense from the Company’s Europe operations. The Company expects these actions will reduce operating costs by approximately $70 million annually and is anticipated to be substantially completed by June 30, 2026. Amarin anticipates that it will incur between approximately $30 million and $37 million in charges related to the restructuring, substantially all of which are cash expenditures for one-time termination benefits and associated costs.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/897448/000095017025089218/0000950170-25-089218-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"between approximately $30 million and $37 million"},{"label":"Affected area","value":"Europe operations"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}